Cover Image
市場調查報告書

核受體ROR伽馬:開發中產品分析

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018

出版商 Global Markets Direct 商品編碼 379066
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
核受體ROR伽馬:開發中產品分析 Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018
出版日期: 2018年07月10日 內容資訊: 英文 106 Pages
簡介

本報告提供以核受體ROR伽馬為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

核受體ROR伽馬 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AbbVie Inc
  • Advinus Therapeutics Ltd
  • Arrien Pharmaceuticals, LLC
  • Aurigene Discovery Technologies Limited
  • Beijing Hanmi Pharmaceutical Co., Ltd.
  • Biogen Inc
  • Brickell Biotech, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Genentech, Inc.
  • Genfit SA
  • GlaxoSmithKline Plc
  • 日本煙草產業
  • Lead Pharma Holding B.V.
  • Nuevolution AB
  • Pfizer Inc.
  • Phenex Pharmaceuticals AG
  • Reata Pharmaceuticals, Inc.
  • 武田藥品工業
  • TEIJIN FIBERS製藥
  • Visionary Pharmaceuticals, Inc.
  • Vitae Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1547TDB

Summary

According to the recently published report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2018'; Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 39 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes.

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (RORγ) is a protein encoded by the RORC gene. RORγ is member of the nuclear receptor family of transcription factors. It exist in two isoforms RORγ and RORγt. RORγ is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R ORγt, appears to be highly restricted to the thymus. RORγ isoform is involved in the regulation of circadian rhythms and RORγt plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.

The report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2018' outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 21, 7 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology and Metabolic Disorders which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Plaque Psoriasis (Psoriasis Vulgaris), Psoriatic Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Asthma, Bladder Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Metastatic Transitional (Urothelial) Tract Cancer, Neuromyelitis Optica (Devic's Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Skin Inflammation, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
  • The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Biogen Inc
  • Boston Pharmaceuticals Inc
  • Brickell Biotech Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Daiichi Sankyo Co Ltd
  • Escalier Biosciences BV
  • Genentech Inc
  • Genfit SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Johnson & Johnson
  • Lead Pharma Holding BV
  • LEO Pharma A/S
  • Lycera Corp
  • Maruho Co Ltd
  • Novartis AG
  • Nuevolution AB
  • Orphagen Pharmaceuticals Inc
  • Pfizer Inc
  • Phenex Pharmaceuticals AG
  • Reata Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • Visionary Pharmaceuticals Inc
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles
  • A-213 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABBV-157 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZD-0284 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BBI-6000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BOS-172767 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CD-12681 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GRC-39815 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-2981278 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IMU-366 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INV-17 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INV-71 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JNJ-3534 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JTE-451 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LP-0186 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LYC-55716 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RTA-1701 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Nuclear Receptor ROR Gamma for Autoimmune Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit RORC for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize RORC for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize ROR Gamma for Gastrointestinal and Immunology Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORC for Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORC for Autoimmune Disorders and Psoriasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORC for Psoriasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis, Inflammatory Bowel Disease, Dermatology and Psoriatic Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SR-1001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SR-2211 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TGFTX-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TMP-778 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 20, 2018: Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of ROR gamma t
  • Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 1701 at the BIO International Convention
  • May 30, 2018: Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting
  • May 21, 2018: Karo Pharma Receives Milestone Payment for RORgamma Project From Pfizer
  • May 16, 2018: Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Model
  • Apr 26, 2018: Nuevolution obtains new data in its internal RORt program supporting effect in human inflammatory bowel diseases
  • Apr 17, 2018: Lycera Presents Clinical Safety and Dose Selection Results for First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 AACR Annual Meeting
  • Apr 05, 2018: Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting
  • Apr 03, 2018: Reata to Present Preclinical Data on RTA 1701, a Novel RORt Inverse Agonist, at Upcoming Immunology Conference
  • Mar 16, 2018: Reata to Present on its Autoimmune and Inflammatory Disorders Drug Candidate at the BIO Asia International Conference
  • Jan 04, 2018: Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab
  • Nov 21, 2017: Lead Pharma Achieves Third Milestone in Sanofi Collaboration for Development of Autoimmune Diseases Treatments
  • Nov 07, 2017: Lycera Presents Tumor Selection Rationale for Phase 2a Study at Society for Immunotherapy of Cancer's (SITC) 2017 Annual Meeting for RORgamma Agonist, LYC-55716
  • Oct 19, 2017: Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a
  • Oct 04, 2017: Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORC Inverse Agonist Program
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indications, H2 2018
  • Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Companies, H2 2018 (Contd..1)
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Companies, H2 2018 (Contd..2), H2 2018
  • Products under Development by Companies, H2 2018 (Contd..3), H2 2018
  • Products under Development by Companies, H2 2018 (Contd..4), H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by AbbVie Inc, H2 2018
  • Pipeline by AstraZeneca Plc, H2 2018
  • Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
  • Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018
  • Pipeline by Biogen Inc, H2 2018
  • Pipeline by Boston Pharmaceuticals Inc, H2 2018
  • Pipeline by Brickell Biotech Inc, H2 2018
  • Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Pipeline by Celgene Corp, H2 2018
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Pipeline by Escalier Biosciences BV, H2 2018
  • Pipeline by Genentech Inc, H2 2018
  • Pipeline by Genfit SA, H2 2018
  • Pipeline by GlaxoSmithKline Plc, H2 2018
  • Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018
  • Pipeline by Johnson & Johnson, H2 2018
  • Pipeline by Lead Pharma Holding BV, H2 2018
  • Pipeline by LEO Pharma A/S, H2 2018
  • Pipeline by Lycera Corp, H2 2018
  • Pipeline by Maruho Co Ltd, H2 2018
  • Pipeline by Novartis AG, H2 2018
  • Pipeline by Nuevolution AB, H2 2018
  • Pipeline by Orphagen Pharmaceuticals Inc, H2 2018
  • Pipeline by Pfizer Inc, H2 2018
  • Pipeline by Phenex Pharmaceuticals AG, H2 2018
  • Pipeline by Reata Pharmaceuticals Inc, H2 2018
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
  • Pipeline by Visionary Pharmaceuticals Inc, H2 2018
  • Dormant Projects, H2 2018
  • Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
Back to Top